Table 3. Endothelial Function, Inflammatory Parameters, and Disease Activity Scores After 16 Weeks of Therapy
VariableTocilizumabAnti–TNF‐αsDMARD
BaselinePost‐TreatmentP ValueBaselinePost‐TreatmentP ValueBaselinePost‐TreatmentP Value
FMD%3.43% [1.28–5.58]5.96% [3.95–7.97]0.03a4.78% [2.13–7.42]6.75% [4.10–9.39]0.092.87% [−2.17 to 7.91]4.84% [2.61–7.07]0.21
CRP, mg/dL3.59 [1.84–5.35]0.16 [0.02–0.31]<0.001a1.62 [0.92–2.32]1.07 [0.16–1.98]0.052.31 [1.00–3.61]1.30 [0.26–2.33]0.07
ESR, mm/h56.3 [37.33–75.30]7.9 [0.81–15.07]<0.001a37.7 [18.64–56.70]28.2 [9.22–47.22]0.1531.8 [17.77–45.92]30.5 [16.00–44.92]0.82
DAS28‐ESR6.73 [6.15–7.32]4.00 [3.39–4.61]<0.001a5.90 [4.69–7.12]4.74 [3.71–5.76]0.03a5.62 [4.88–6.36]4.04 [3.25–4.83]0.001a
DAS28‐CRP5.87 [5.29–6.44]4.02 [3.54–4.51]<0.001a5.34 [4.22–6.47]4.35 [3.40–5.29]0.049a5.15 [4.43–5.88]3.53 [2.78–4.29]0.001a
HAQ‐DI1.88 [1.60–2.15]1.40 [1.04–1.77]0.004a1.69 [1.07–2.32]1.37 [0.73–2.02]0.101.22 [0.89–1.56]0.80 [0.38–1.23]0.04a
  • Values are expressed as mean [95% CI]. Anti–TNF‐α indicates anti–tumor necrosis factor α; DAS28‐CRP, Disease Activity Score of 28 joints, using C‐reactive protein (CRP); ESR, erythrocyte sedimentation rate; FMD%, flow‐mediated dilation percentage variation; HAQ‐DI, Health Assessment Questionnaire—Disability Index; sDMARD, synthetic disease‐modifying antirheumatic drug.

  • a Statistically significant.